<DOC>
	<DOCNO>NCT01868828</DOCNO>
	<brief_summary>A multicenter , double arm , prospective randomize control phase 4 study . Approximately 50 previously untreated subject multiple myeloma enrol . The study consist 6 phase , screen , treatment follow-up .</brief_summary>
	<brief_title>A Study PAD Versus Velcade , Cyclophosphamide Dexamethasone ( VCD ) Treatment Subjects With Multiple Myeloma</brief_title>
	<detailed_description>Screening At screen visit , informed consent obtain subject deem potentially eligible enrollment study , accord protocol-specified inclusion exclusion criterion . Treatment Eligible patient randomly assign receive either treatment PAD VCD . All eligible subject evaluate 4 cycle treatment . According assessment researcher willingness patient decide whether autologous stem-cell transplantation ( ASCT ) . Suitable transplant patient accept hematopoietic stem cell transplantation . Not suitable transplant patient continue accept treatment 8 cycle . The patient accept 4 cycle treatment receive efficacy evaluation . Follow-up All patient receive 12 month follow-up treatment period . Follow-up 4 , 6 , 8 12 month treatment period respectively . Subjects disease progression accept resistance myeloma therapy 12 month follow-up phase stop assess study start follow survival status every 6 month telephone interview research center follow-up . All patient accept follow-up survival last case patient complete follow-up . Safety evaluate throughout study assessment adverse event ( AEs ) , physical examination , vital sign clinical laboratory finding .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Men woman age &lt; 65 year . 2 . Previously untreated subject multiple myeloma . 3 . No clinically significant cardiac amyloidosis ( Echocardiography septal≤10mm , brain natriuretic peptide ( BNP ) &lt; 500 ) . 4 . Pulmonary infection ( ) must control effectively . 5 . Chronic viral hepatitis ( ) must control effectively . ( Subjects HBs Ag positive need monitor hepatitis B virusDNA ( HBVDNA ) quantitative test regularly）； 6 . Liver function ( aminotransferase , bilirubin） ? 2 x upper limit normal ( ULN ) . 7 . Expected lifetime More 3 month . 8 . Be able read sign ( legallyacceptable representative must sign ) inform consent document indicate understand purpose procedure require study willing participate study . 1 . Patients relapse multiple myeloma . 2 . Need change program accord researcher ' evaluate patient disease progression treatment . 3 . Had uncontrolled severe cardiovascular disease . Had myocardial infarction within 6 month enrolment , New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , clinically significant pericardial disease , cardiac amyloidosis . 4 . Has history allergic reaction compound contain boron mannitol . 5 . Severe neuropathy may affect treatment , accord researcher determine . 6 . According program investigator 's judgment , patient suffer serious physical illness mental illness may interfere participation clinical study . 7 . Concurrent treatment another investigational agent . 8 . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Combination Therapy</keyword>
</DOC>